Using IP law as a medical patient safety tool: efforts from the US and China
by Robert Jameson, James Chin, Frank Peo, Luis Gonzales, Daniel Lorence
International Journal of Intellectual Property Management (IJIPM), Vol. 3, No. 2, 2009

Abstract: The unregulated manufacture of prescription drugs, sold under a known generic or brand name, poses an increasing safety risk to unsuspecting healthcare consumers around the world. Those who receive a counterfeit medication may be at risk for a number of dangerous health consequences. Patients may experience unexpected side effects, allergic reactions, or worsening of their medical condition. Many counterfeits do not contain any active ingredient and instead use inert substances which provide no medical treatment benefit. Counterfeit medications may also contain incorrect ingredients, improper dosages of the correct ingredients, or may contain hazardous ingredients. As a collaborative countermeasure model, we summarise here joint anti-counterfeiting efforts through intellectual property rights (IPR) enforcement by the US and China. Such cooperative work serves as a model for enforcement and illustrates how intellectual property (IP) law is being applied across borders to combat unregulated prescription drug manufacture and sale.

Online publication date: Sun, 15-Feb-2009

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com